Interleukin-2 for the treatment of human immunodeficiency virus infection

Drugs of Today

Volumn 42, Issue 12, 2006, Pages 791-801

  Temesgen, Zelalem ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; INTERLEUKIN 2; INTERLEUKIN 2 DERIVATIVE; LAMIVUDINE; NELFINAVIR; PEGYLATED INTERLEUKIN 2; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

AEROSOL; ARTHRALGIA; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; KIDNEY CARCINOMA; LIPOSOMAL DELIVERY; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; REVIEW; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INTERLEUKIN-2;

EID: 33846986439     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.12.1025703     Document Type: Review

References (70)

1. Palella, F.J. Jr., Delaney, K.M., Moorman, A.C. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338: 853-60.
2. Torres, R.A., Barr, M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997, 336: 1531-2.
3. Carcelain, G., Debre, P., Autran, B. Reconstitution of CD4p T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001, 13: 483-8.
4. Deayton, J.R., Sabin, C.A., Britt, W.B. et al. Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. AIDS 2002, 16: 2129-35.
5. Foudraine, N.A., Hovenkamp, E., Notermans, D.W. et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999, 13: 177-84.
6. Deayton, J.R., Sabin, C.A., Britt, W.B. et al. Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. AIDS 2002, 16: 2129-35.
7. Pitcher, C.J., Quittner, C., Peterson, D.M. et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999, 5: 518-25.
8. Piketty, C., Castiel, P., Belec, L. et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998, 12: 745-50.
9. Connick, E., Lederman, M., Kotzin, B. et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000, 181: 358-63.
10. Lederman, M.M., Valdez, H. Immune restoration with antiretroviral therapies: Implications for clinical management. JAMA 2000, 284: 223-8.
11. Watson, J.D., Gillis, D.Y., Mochizuki, S. Molecular characterization of interleukin 2. Fed Proc 1983, 42: 2747-52.
12. Smith, K.A. Interleukin-2: Inception, impact, and implications. Science 1988, 240: 1169-76.
13. Kasahara, T., Hooks, J.J., Dougherty, S.F., Oppenheim, J.J. Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol 1983, 130: 1784-9.
14. Rook, A.H., Masur, H., Lane, H.C. et al. Inter-leukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983, 72: 398-403.
15. Rook, A.H., Masur, H., Lane, H.C. et al. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. J Immunol 1985, 134: 1503-7.
16. Chinen, J., Shearer, W.T. Molecular virology and immunology of HIV infection. J Allergy Clin Immunol 2002, 110: 189-98.
17. Lane, H.C., Fauci, A.S. Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol 1985, 3: 477-500.
18. Bowen, D.L., Lane, H.C., Fauci, A.S. Immunopathogenesis of the acquired immunodeficiency restored by antiviral or immune-based therapies. Nat Med 1997, 3: 533-40.
19. Connors, M., Kovacs, J.A., Krevat, S. et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997, 3: 533-40.
20. Murray, H.W., Weite, K., Jacobs, J.L., Rubin, B.Y., Mertelsmann, R., Roberts, R.B. Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest 1985, 76: 1959-64.
21. Bell, S.J., Cooper, D.A., Kemp, B.E., Doherty, R.R., Penny, R. Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI). Clin Exp Immunol 1992, 90: 6-12.
22. Kovacs, J.A., Lempicki, R.A., Sidorov, I.A. et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005, 115: 2139-48.
23. Kinter, A., Fauci, A.S. Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement. Immunol Res 1996, 15: 1-15.
24. Kinter, A.L., Bende, S.M., Hardy, E.C., Jackson, R., Fauci, A.S. Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995, 92: 10985-9.
25. Krowka, J., Stites, D., Mills, J. et al. Effects of interleukin 2 and large envelope glycoprotein (gp 120) of human immunodeficiency virus (HIV) on lymphocyte proliferative responses to cytomegalovirus. Clin Exp Immunol 1988, 72: 179-85.
26. Adachi, Y., Oyaizu, N., Than, S., McCloskey, T.W., Pahwa, S. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection. Correlation with its ability to block culture-induced down-modulation of Bcl-2. J Immunol 1996, 157: 4184-93.
27. Sereti, I., Imamichi, H., Natarajan, V. et al. In vivo expansion of CD4+CD45RO-CD25+T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005, 115: 1839-47.
28. Sereti, I., Anthony, K.B., Martinez-Wilson, H. et al. IL-2-induced CD4+T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004, 104: 775-80.
29. Kern, P., Toy, J., Dietrich, M. Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. Blut 1985, 50: 1-6.
30. Ernst, M., Kern, P., Flad, H.D., Ulmer, A.J. Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC). J Clin Immunol 1986; 6: 170-81.
31. Volberding, P., Moody, D.J., Beardslee, D., Bradley, E.C., Wofsy, C.B. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987, 3: 115-24.
32. Schwartz, D.H., Skowron, G., Merigan, T.C. Safety and effects of interleukin 2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1991, 4: 11-23.
33. Piscitelli, S.C., Forrest, A., Vogel, S. et al. Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 1998, 64: 492-8.
34. de Boer, A.W., Markowitz, N., Lane, H.C. et al. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells. Clin Immunol 2003, 106: 188-96.
35. Kovacs, J.A., Baseler, M., Dewar, R.J. et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Eng J Med 1995, 332: 567-75.
36. Kovacs, U.A., Vogel, S., Albert, J.M. et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Eng J Med 1996, 335: 1350-6.
37. Carr, A., Emery, S., Lloyd, A. et al.; for the Australian IL-2 Study Group. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study. J Infect Dis 1998, 178: 992-9.
38. Levy, Y., Capitant, C., Houhou, S. et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomized controlled trial. ANRS 048 study group. Lancet 1999, 353: 1923-9.
39. Emery, S., Capra, W.B., Cooper, D.A. et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis 2000, 182: 428-34.
40. Piscitelli, S.C., Wells, M.J., Metcalf, J.A., Baseler, M., Stevens, R., Davey, R.T. Jr. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. Pharmacotherapy 1996, 16: 754-9.
41. Davey, R.T. Jr., Chaitt, D.G., Piscitelli, S.C. et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997, 175: 781-9.
42. Davey, R.T. Jr., Chaitt, D.G., Albert, J.M. et al. A randomized trial of high versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999, 179: 849-58.
43. 3. J Infect Dis 2000, 181: 1614-21.
44. Ruxrungtham, K., Suwanagool, S. Tavel, J.A. et al. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. AIDS 2000, 14: 2509-13.
45. Davey, R.T. Jr., Murphy, R.L., Graziano, P.M. et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA 2000, 284: 183-9.
46. Flad, H.D., Ernst, M., Kern, P. A phase I/II trial of recombinant interleukin-2 in AIDS/ARC: Alterations of phenotypes of peripheral blood mononuclear cells. Lymphokine Res 1986, 5 (Suppl. 1): S171-6.
47. Kern, P., Toy, J., Dietrich, M. Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. Blut 1985, 50: 1-6.
48. Volberding, P., Moody, D.J., Beardslee, D., Bradley, E.C., Wofsy, C.B. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Human Retroviruses 1987, 3: 115-24.
49. David, D., Bani, L., Moreau, J.L. et al. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Nat Acad Sci USA 1998, 95: 11348-53.
50. Hengge, U.R., Goos, M., Esser, S. et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998, 12: F225-34.
51. Tambussi, G., Ghezzi, S., Nozza, S. et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 IL-2 regimens with antiviral drug therapy. J Infect Dis 2001, 183: 1476-84.
52. Stellbrink, H.J., van Lunzen, J., Westby, M. et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002, 16: 1479-87.
53. 3: CPCRA 059. J Acquir Immune Defic Syndr 2002, 29: 221-31.
54. Levy, Y., Durier, C., Krzysiek, R. et al. ANRS 079 Study Group. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial. AIDS 2003, 17: 343-51.
55. Markowitz, N., Bebchuk, J.D., Abrams, D.I.; Terry Beirn Community Program for Clinical Research on AIDS. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2. Clin Infect Dis 2003, 37: e115-20.
56. David, D., Nait-Ighil, L., Dupont, B., Mara, J., Gachot, B., Theze, J. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J Infect Dis 2001, 183: 730-5.
57. Arno, A., Ruiz, L., Juan, M. et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons. J Infect Dis 1999, 180: 56-60.
58. Lalezari, J.P., Beal, J.A., Ruane, P.J. et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: A randomized controlled trial. HIV Clin Trials 2000, 1: 1-15.
59. 3: ACTG 328 - Final results at 84 weeks. 8th Conf Retrovir Oppor Infect, Chicago 2001, Abst. 17.
60. Katlama, C., Carcelain, G., Duvivier, C. et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: The ILSTIM study - ANRS 082. AIDS 2002, 16: 2027-34.
61. Marchetti, G., Meroni, L., Varchetta, S. et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: Results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 2002, 186: 606-16.
62. Routy, J.P.; for the International SILCAAT Team. Demographics and visit compliance in SILCAAT, a large international phase III clinical endpoint trial with IL-2 as an immune-based therapy adjunctive to ART. XIV Int Conf AIDS, Barcelona 2002, Abst. WePeB5982.
63. Emery, S., Abrams, D.I., Cooper, D.A. et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: Rationale, design, and methods of ESPRIT. Control Clin Trials 2002, 23: 198-220.
64. Youle, M., Emery, S., Fisher, M. et al. A randomized trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-Infected patients: The UK-Vanguard Study. PLoS Clin Trials 2006, 1: e3 DOI: 10.1371.
65. Huland, E., Huland, H., Heinzer, H. Interleukin-2 by inhalation: Local therapy for metastatic renal cell carcinoma. J Urol 1992, 147: 344-8.
66. Huland, E., Heinzer, H., Mir, T.S., Huland, H. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience. Cancer J Sci Am 1997, 3 (Suppl. 1): S98-105.
67. Huland, E., Heinzer, H., Huland, H. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma. Folia Biol (Krakow) 2000, 46: 241-50.
68. Huland, E., Burger, A., Fleischer, J. et al. Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: An outcome study. Folia Biol 2003, 49: 183-95.
69. Huland, E., Heinzer, H., Huland, H., Yung, R. Overview of interleukin-2 inhalation therapy. Cancer J Sci Am 2000, 6 (Suppl. 1): S104-12.
70. Skubitz, K.M., Anderson, P.M. Inhalational interleukin-2 liposomes for pulmonary metastases: A phase I clinical trial. Anticancer Drugs 2000, 11: 555-63.